希罗达治疗老年晚期消化道肿瘤的临床观察

Clinical observe of capecitabine regimen as main therapy for esnile patients with digestive system cancer

目的观察希罗达治疗老年晚期消化道肿瘤的疗效及安全性。方法对33例具有可测量指标的老年晚期消化道肿瘤患者采用希罗达单药每天2000mg,分早晚2次口服,连续服用2周、休息1周为1个周期,每例患者至少进行2个周期的治疗,结束后进行评价。结果全组33例客观疗效为,CR 0例,PR 12例、NC 11例、PD 10例。(CR+PR)12例。总有效率36.36%肿瘤控制率为(CR+PR+NC)69.70%;部分PD患者主观症状有减轻。主要毒副反应为手足综合征,皮肤色素沉着,恶心呕吐,厌食,腹泻,疲劳,口炎等,少数患者出现胆红素和丙氨酸转氨酶轻度升高及轻至中度贫血和白细胞及血小板减下降。结论对晚期老年消化道肿瘤患者来说,希罗达治疗有效并安全。

Aim To evaluate the objective response rate and toxicity of capecitabine regimen as main therapy for patients with digestive system cancer. Methods Thlrty-three patients with digestive system cancer had capecitabine 2000 mg daily in 21-day cycle of therapy for 2 cycles. Results The thirty-three patients were assessable for efficacy and toxicity. No patient achieved a complete response and 12 patients had partial responses,with an overall response rate of 36.36%. The most common adverse effects were gastrointestinal response and myelosuppression,but could be endured. There was no chemotherapy-related death. Conclusions The capecitabine is effective and well tolerated as main therapy for senil patients with digestive system cancer.